| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/14/2007 | CN1300113C Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors |
| 02/14/2007 | CN1300110C Hydroxamate derives useful as deacetylase inhibitors |
| 02/14/2007 | CN1300083C Biphenyl undecanone compounds with anticancer activity |
| 02/14/2007 | CN1299774C Slow released anticancer combination of medication embedded the interior of the body |
| 02/14/2007 | CN1299773C Anti-cancer medicine composition |
| 02/14/2007 | CN1299772C Anti-cancer medicine composition |
| 02/14/2007 | CN1299769C Human papilloma virus and heat shock protein recombinant protein vaccine and use thereof |
| 02/14/2007 | CN1299765C Thymosin peptide oral tablet and its preparation method |
| 02/14/2007 | CN1299764C Preparing method of liposome endothelial chalone |
| 02/14/2007 | CN1299749C Medicine for treating lung cancer and its preparation method |
| 02/14/2007 | CN1299705C Anti-tumour medicine, its preparing method and novel use |
| 02/14/2007 | CN1299695C Liquid embolism agent for intracranial aneurysm and its preparing process |
| 02/14/2007 | CN1299683C Celecoxib compositions |
| 02/14/2007 | CN1299682C Use of pyrazoline derivatives in preparation of medicament for prevention and/or treatment of proliferative cell diseases |
| 02/14/2007 | CN1299675C Composition of cupresulflavone and its preparation |
| 02/14/2007 | CN1299674C Slow released combination of anticancer drugs embedded in vivo |
| 02/14/2007 | CN1299672C Extracts from sophora,production method and purposes thereof |
| 02/14/2007 | CN1299668C Nanometer realgar solid dispersion and its preparation method |
| 02/13/2007 | US7176327 Water soluble, biologically inert Pt(IV) compounds which can be converted to cytotoxic Pt(II) species by photoactivation; reduced side effect anticancer drugs |
| 02/13/2007 | US7176326 β-Lactams, methods for the preparation of taxanes, and sidechain-bearing taxanes |
| 02/13/2007 | US7176302 Delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is |
| 02/13/2007 | US7176294 Transcription factor, BP1 |
| 02/13/2007 | US7176241 Aromatic or heteroaromatic compounds containing amide group are useful as inhibitor of dihydroorotate dehydrogenase |
| 02/13/2007 | US7176233 Salinosporamides and methods for use thereof |
| 02/13/2007 | US7176232 Fermentation product of marine actinomyces strains; antiproliferative agents; anticancer agents |
| 02/13/2007 | US7176229 Pyrrolidine antiinflammatory agents for rheumatoid arthritis, osteoarthritis; antiallergens for asthma, chronic bronchitis, allergic rhinitis, adult respiratory distress syndrome, chronic pulmonary inflammatory disease; reduce or eliminate adverse CNS side effects associated with prior PDE4 inhibitors |
| 02/13/2007 | US7176227 Amine compounds and use thereof |
| 02/13/2007 | US7176217 such as N-Hydroxy-2-[(4-methoxyphenyl)sulfonyl]-2-azabicyclo[2.2.1]heptane-3-carboxamide, used in cosmetics or drugs as gelatinase inhibitors, for preventing skin aging or wrinkling; preventing diseases due to abnormal metabolism of tissue matrices such as arthritis, ulcers, metastasis or tumors |
| 02/13/2007 | US7176215 Bicyclic oxopyridine and oxopyrimidine derivatives |
| 02/13/2007 | US7176213 For example, 1-(9-benzylamino-10-cyano-imidazo[1,2-a]quinolin-2-carbonyl)pyrrolidine; may be used for the treatment of diseases such as asthma, glaucoma, tumors, allergic and inflammatory diseases, ischemia, hypoxia, arrythmia and renal diseases |
| 02/13/2007 | US7176212 2,4-diamino pyrimidine compounds having anti-cell proliferative activity |
| 02/13/2007 | US7176199 Useful as a preventive or/and a therapeutic agent for a disease in which alpha v beta 3 integrin is involved |
| 02/13/2007 | US7176189 Methods for regeneration of a mammalian lens |
| 02/13/2007 | US7176180 Fusion proteins; immunoglobulins; kits |
| 02/13/2007 | US7176178 Protein H and its fragments/derivatives are capable of interacting with nucleophosmin/B23, actin, NPM/B23, protein SET or hnRNP A2/B1 |
| 02/13/2007 | US7176164 1,3-selenazolin derivatives and process for preparing the same |
| 02/13/2007 | US7176035 Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction |
| 02/13/2007 | US7176020 Detection and monitoring anticarcinogenic agents; obtain tissue, infect with cancer cells, incubate with test compound, monitor antiproliferative activity |
| 02/13/2007 | US7175997 BMP-11 compositions |
| 02/13/2007 | US7175849 Polypeptide for use in the treatment of viral disorders |
| 02/13/2007 | CA2359510C .omega.-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| 02/13/2007 | CA2358840C Methods and kits comprising an estrogen agonist/antagonist for improving vascular health |
| 02/13/2007 | CA2285037C Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same |
| 02/13/2007 | CA2254759C Inhibitors of prenyl transferases |
| 02/13/2007 | CA2124958C Inhibitory immunoglobulin polypeptides to human pdgf beta receptor |
| 02/13/2007 | CA2122236C Quinolines and their analogs |
| 02/09/2007 | CA2554969A1 Chemoprotectants from crucifer seeds and sprouts |
| 02/08/2007 | WO2007016556A1 Multifunctional polymers for promotion of opsonization of target cells and organisms |
| 02/08/2007 | WO2007016354A1 Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| 02/08/2007 | WO2007015871A1 Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| 02/08/2007 | WO2007015870A2 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| 02/08/2007 | WO2007015757A2 Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators |
| 02/08/2007 | WO2007015587A1 Apoptosis promoter, cell proliferation inhibitor, prophylactic/therapeutic agent for cancer, screening method for the promoter, inhibitor or agent |
| 02/08/2007 | WO2007015578A1 Method for assay on the effect of vascularization inhibitor |
| 02/08/2007 | WO2007015569A1 Method for prediction of the efficacy of vascularization inhibitor |
| 02/08/2007 | WO2007015567A1 Cyclic amine compound |
| 02/08/2007 | WO2007015280A1 Benzodiazepine derivatives and uses thereof in medical field |
| 02/08/2007 | WO2007015175A2 Use of pp-1 inhibitors to prevent missplicing events |
| 02/08/2007 | WO2007015171A2 Method of treating patients with a mucinous glycoprotein (muc-1) vaccine |
| 02/08/2007 | WO2007015112A1 Antitumoral compounds |
| 02/08/2007 | WO2007014991A1 Antibodies directed against a ldl receptor |
| 02/08/2007 | WO2007014743A2 Cd33-specific single-chain immunotoxin and method of use |
| 02/08/2007 | WO2007014707A1 Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents |
| 02/08/2007 | WO2007014687A1 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof |
| 02/08/2007 | WO2007014652A1 TREATMENT OF TUMOURS WITH IKK-ß INHIBITORS |
| 02/08/2007 | WO2007014608A1 Quadratic acid ii derivatives |
| 02/08/2007 | WO2007014524A1 Erianin salts, their preparation methods and pharmaceutical compositions containing the same |
| 02/08/2007 | WO2007014460A1 Cancerous disease modifying antibodies |
| 02/08/2007 | WO2007014459A1 Cancerous disease modifying antibodies |
| 02/08/2007 | WO2007014458A1 Cancerous disease modifying antibodies |
| 02/08/2007 | WO2007014457A1 Cancerous disease modifying antibodies |
| 02/08/2007 | WO2007014456A1 Cancerous disease modifying antibodies |
| 02/08/2007 | WO2007014455A1 Cancerous disease modifying antibodies |
| 02/08/2007 | WO2006135796A3 Crystalline forms of a pyrrolotriazine compound |
| 02/08/2007 | WO2006130458A3 Antibodies directed to cd20 and uses thereof |
| 02/08/2007 | WO2006129168A3 Bicyclic derivatives for the treatment of abnormal cell growth |
| 02/08/2007 | WO2006116309A3 Polymorphic and amorphous salt forms of squalamine dilactate |
| 02/08/2007 | WO2006101244A3 Method and composition for treating mucosal disorders |
| 02/08/2007 | WO2006087759A3 Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field |
| 02/08/2007 | WO2006078422A3 Methods for modulating tumor growth and metastasis |
| 02/08/2007 | WO2006062732A3 Compounds acting at the centrosome |
| 02/08/2007 | WO2006055526B1 Compositions useful to treat ocular neovascular diseases and macular degeneration |
| 02/08/2007 | WO2006050834A3 Antibodies against tenascin-c |
| 02/08/2007 | WO2006048633A3 Combination comprising zd6474 and an antiandrogen |
| 02/08/2007 | US20070033669 Semaphorin gene family |
| 02/08/2007 | US20070032653 N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. |
| 02/08/2007 | US20070032640 Cytokine receptor |
| 02/08/2007 | US20070032545 Antibiotic fki-1778 and process for producing the same |
| 02/08/2007 | US20070032538 Use of compounds |
| 02/08/2007 | US20070032532 Hsp90 family protein inhibitors |
| 02/08/2007 | US20070032528 inhibitors of vascular endothelial growth factor receptor tyrosine kinase; antiproliferative agents; antitumor; 4-Hydroxy-3-(5-methylbenzimidazol-2-yl)hydropyridino[3,4-b]pyridin-2-one; nitrogen containing cyclic compounds |
| 02/08/2007 | US20070032518 Compounds and methods of use |
| 02/08/2007 | US20070032515 Anaplastic lymphoma kinase modulators and methods of use |
| 02/08/2007 | US20070032513 Antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases;1-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}methyl)-L-prolinamide |
| 02/08/2007 | US20070032508 Quinazoline derivatives as tyrosine kinase inhibitors |
| 02/08/2007 | US20070032507 Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug. |
| 02/08/2007 | US20070032492 Cytokine Inhibitors |
| 02/08/2007 | US20070032476 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof |
| 02/08/2007 | US20070032474 Use of a compound of formula 1 for making a pharmaceutical composition |
| 02/08/2007 | US20070032446 Gapped 2' modified oligonucleotides |